{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:21:50Z","timestamp":1783549310515,"version":"3.55.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eprac.2025.06.027","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T20:41:31Z","timestamp":1751661691000},"page":"1509-1520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Noninsulin Therapies in Management of Type 1 Diabetes"],"prefix":"10.1016","volume":"31","author":[{"given":"Zeb I.","family":"Saeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayachidambaram","family":"Ambalavanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie Natasha","family":"Rayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palak","family":"Patadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viral N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-8587(24)00279-1","article-title":"Treatment regimens and glycaemic outcomes in more than 100 000 children with type 1 diabetes (2013-22): a longitudinal analysis of data from paediatric diabetes registries","volume":"13","author":"Zimmermann","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.027_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/dia.2018.0384","article-title":"State of type 1 diabetes management and outcomes from the T1D Exchange in 2016-2018","volume":"21","author":"Foster","year":"2019","journal-title":"Diabetes Technol Ther"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2337\/dc23-0495","article-title":"Association between diabetes technology use and glycemic outcomes in adults with type 1 diabetes over a decade","volume":"46","author":"Karakus","year":"2023","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.027_bib4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1001\/jama.280.2.140","article-title":"Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial","volume":"280","author":"Purnell","year":"1998","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.027_bib5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(21)00246-1","article-title":"Obesity in people living with type 1 diabetes","volume":"9","author":"Van der Schueren","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2025.06.027_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000539847","article-title":"Variability in body mass index during 2018-2021 for people with type 1 diabetes: real world data from the USA, Germany, and australasia","author":"Narayan","year":"2024","journal-title":"Horm Res Paediatr"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12933-024-02145-x","article-title":"Double diabetes-when type 1 diabetes meets type 2 diabetes: definition, pathogenesis and recognition","volume":"23","author":"Bielka","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.027_bib8","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1111\/dom.13848","article-title":"Double diabetes: a distinct high-risk group?","volume":"21","author":"Kietsiriroje","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12933-023-01791-x","article-title":"Estimated glucose disposal rate is associated with retinopathy and kidney disease in young people with type 1 diabetes: a nationwide observational study","volume":"22","author":"Linn","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.027_bib10","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/dom.13110","article-title":"Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes","volume":"20","author":"Nystr\u00f6m","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2025.06.027_bib11","series-title":"Diabetes in America","article-title":"Mortality in type 1 diabetes","author":"Secrest","year":"2018"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2025.06.027_bib12","first-page":"S158","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142024","volume":"47","year":"2023","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.027_bib13","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.eprac.2025.06.027_bib14","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.027_bib15","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.027_bib16","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.eprac.2025.06.027_bib17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/dom.13972","article-title":"Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: observations from the DEPICT clinical trial programme","volume":"22","author":"Gordon","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib18","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","article-title":"Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials","volume":"8","author":"Groop","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib19","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the north American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib20","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes","volume":"42","author":"van Raalte","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1089\/dia.2020.0068","article-title":"Improvement in patient-reported outcomes in adults with type 1 diabetes treated with sotagliflozin plus insulin versus insulin alone","volume":"23","author":"Danne","year":"2021","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"10.1016\/j.eprac.2025.06.027_bib22","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/dom.15047","article-title":"Sotagliflozin, a dual sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes","volume":"25","author":"Stougaard","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib23","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA(1c) and hypoglycemia reductions at 24 and 52 Weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib24","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1111\/dom.13807","article-title":"Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: a randomized, double-blind, phase 3 trial","volume":"21","author":"Kaku","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib25","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/dom.14060","article-title":"Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial","volume":"22","author":"Mathieu","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.027_bib26","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/dc15-1037","article-title":"Twelve-Week treatment with liraglutide as add-on to insulin in normal-weight patients with poorly controlled type 1 diabetes: a randomized, placebo-controlled, double-blind parallel study","volume":"38","author":"Frandsen","year":"2015","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib27","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.027_bib28","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S2213-8587(15)00436-2","article-title":"Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial","volume":"4","author":"Dejgaard","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2025.06.027_bib29","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.12841","article-title":"Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes","volume":"19","author":"Dejgaard","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib30","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: the ADJUNCT TWO randomized trial","volume":"39","author":"Ahr\u00e9n","year":"2016","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.027_bib31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2337\/dc15-1136","article-title":"Addition of liraglutide to insulin in patients with type 1 diabetes: a randomized placebo-controlled clinical trial of 12 weeks","volume":"39","author":"Kuhadiya","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/dom.13063","article-title":"Beyond glycaemic control: a cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes","volume":"20","author":"Dub\u00e9","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.027_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/dom.14567","article-title":"Liraglutide changes body composition and lowers added sugar intake in overweight persons with insulin pump-treated type 1 diabetes","volume":"24","author":"Schmidt","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.027_bib34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: the Lira Pump trial-a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.027_bib35","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/dom.14121","article-title":"Exenatide extended release in patients with type 1 diabetes with and without residual insulin production","volume":"22","author":"Herold","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib36","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dom.14090","article-title":"Liraglutide treatment in overweight and obese patients with type 1 diabetes: a 26-week randomized controlled trial; mechanisms of weight loss","volume":"22","author":"Ghanim","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.027_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S2213-8587(20)30030-9","article-title":"Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial","volume":"8","author":"Johansen","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib38","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1111\/dom.14078","article-title":"Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: a randomized double-blind placebo-controlled trial","volume":"22","author":"Johansen","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.027_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/dom.14568","article-title":"Effects of short-acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes","volume":"24","author":"Johansen","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.027_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101433","article-title":"Dulaglutide and insulin microsecretion in people with type 1 diabetes (DIAMOND-GLP-1): a randomized double-blind placebo-controlled trial","volume":"49","author":"Thivolet","year":"2023","journal-title":"Diabetes Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.027_bib41","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1111\/dom.15889","article-title":"Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): a randomized, double-blind, placebo-controlled trial","volume":"26","author":"Dejgaard","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.027_bib42","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-024-03463-z","article-title":"Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial","volume":"31","author":"Pasqua","year":"2025","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.027_bib43","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","article-title":"Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives","volume":"18","author":"Cefalo","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"10354","key":"10.1016\/j.eprac.2025.06.027_bib45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.027_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100851","article-title":"SGLT2 inhibitor use in chronic kidney disease: supporting cardiovascular, kidney, and metabolic health","volume":"6","author":"Madero","year":"2024","journal-title":"Kidney Med"},{"issue":"22","key":"10.1016\/j.eprac.2025.06.027_bib47","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.027_bib48","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","article-title":"SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits","volume":"65","author":"Marilly","year":"2022","journal-title":"Diabetologia"},{"issue":"5","key":"10.1016\/j.eprac.2025.06.027_bib49","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2025.06.027_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1171886","article-title":"Efficacy of combination therapy with GABA, a DPP-4i and a PPI as an adjunct to insulin therapy in patients with type 1 diabetes","volume":"14","author":"Rabinovitch","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2337\/dc22-0490","article-title":"Low-dose empagliflozin as adjunct to hybrid closed-loop insulin therapy in adults with suboptimally controlled type 1 diabetes: a randomized crossover controlled trial","volume":"46","author":"Pasqua","year":"2023","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib55","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2337\/dc24-0212","article-title":"Combination SGLT2 inhibitor and glucagon receptor antagonist therapy in type 1 diabetes: a randomized clinical trial","volume":"48","author":"Boeder","year":"2025","journal-title":"Diabetes Care"},{"issue":"Suppl 7","key":"10.1016\/j.eprac.2025.06.027_bib56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/dom.15921","article-title":"Continuous ketone monitoring: exciting implications for clinical practice","volume":"26","author":"Kong","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib57","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"21","key":"10.1016\/j.eprac.2025.06.027_bib58","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/ajhp\/zxz179","article-title":"Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus","volume":"76","author":"Guyton","year":"2019","journal-title":"Am J Health Syst Pharm"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.027_bib59","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/dom.14050","article-title":"Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight people with type 1 diabetes","volume":"22","author":"Dub\u00e9","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/dia.2024.0328","article-title":"Effectiveness of semaglutide and tirzepatide in overweight and obese adults with type 1 diabetes","volume":"27","author":"Snell-Bergeon","year":"2025","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib61","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/cd24-0067","article-title":"Insulin titration recommendations when using glucagon-like peptide 1 receptor agonist therapy in adults with type 1 diabetes","volume":"43","author":"Saeed","year":"2024","journal-title":"Clin Diabetes"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib65","doi-asserted-by":"crossref","DOI":"10.1111\/dme.15377","article-title":"Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): study protocol of a phase 2 double-blinded randomised placebo-controlled trial","volume":"41","author":"Frampton","year":"2024","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib68","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1464-5491.2006.01966.x","article-title":"The effect of metformin on blood glucose control in overweight patients with Type 1 diabetes","volume":"23","author":"Khan","year":"2006","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0003363","article-title":"Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study","volume":"3","author":"Lund","year":"2008","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.027_bib70","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1742-7843.2009.00380.x","article-title":"The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control","volume":"105","author":"Jacobsen","year":"2009","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.eprac.2025.06.027_bib71","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000355513","article-title":"Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus","volume":"80","author":"Codner","year":"2013","journal-title":"Horm Res Paediatr"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.027_bib72","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/pedi.12140","article-title":"Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study","volume":"16","author":"Nadeau","year":"2015","journal-title":"Pediatr Diabetes"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib73","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137525","article-title":"A randomized, double-blind, placebo-controlled trial of adjunctive metformin therapy in overweight\/obese youth with type 1 diabetes","volume":"10","author":"Nwosu","year":"2015","journal-title":"PLoS One"},{"issue":"21","key":"10.1016\/j.eprac.2025.06.027_bib74","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1001\/jama.2015.16174","article-title":"Effect of metformin added to insulin on glycemic control among overweight\/obese adolescents with type 1 diabetes: a randomized clinical trial","volume":"314","author":"Libman","year":"2015","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.027_bib75","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1210\/jc.2017-00781","article-title":"Effect of metformin on vascular function in children with type 1 diabetes: a 12-month randomized controlled trial","volume":"102","author":"Anderson","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.027_bib76","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S2213-8587(17)30194-8","article-title":"Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial","volume":"5","author":"Petrie","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"25","key":"10.1016\/j.eprac.2025.06.027_bib77","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1161\/CIRCULATIONAHA.118.035525","article-title":"Metformin improves insulin sensitivity and vascular health in youth with type 1 diabetes mellitus","volume":"138","author":"Bjornstad","year":"2018","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.eprac.2025.06.027_bib78","doi-asserted-by":"crossref","first-page":"3265","DOI":"10.1210\/jc.2019-00129","article-title":"Metformin improves peripheral insulin sensitivity in youth with type 1 diabetes","volume":"104","author":"Cree-Green","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.027_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.261","article-title":"Effect of metformin on the high-density lipoprotein proteome in youth with type 1 diabetes","volume":"4","author":"Gourgari","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.eprac.2025.06.027_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109857","article-title":"Effect of metformin as an add-on therapy on neuregulin-4 levels and vascular-related complications in adolescents with type 1 diabetes: a randomized controlled trial","volume":"186","author":"Elbarbary","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib81","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1463-1326.2009.01079.x","article-title":"Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes","volume":"11","author":"Lund","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.027_bib82","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/dom.14350","article-title":"Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: the REMOVAL trial","volume":"23","author":"Timmons","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib83","doi-asserted-by":"crossref","first-page":"526","DOI":"10.20452\/pamw.1925","article-title":"Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low-density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study","volume":"123","author":"Burchardt","year":"2013","journal-title":"Pol Arch Med Wewn"},{"issue":"7-8","key":"10.1016\/j.eprac.2025.06.027_bib84","doi-asserted-by":"crossref","first-page":"514","DOI":"10.20452\/pamw.3527","article-title":"Association between adjunctive metformin therapy in young type 1 diabetes patients with excess body fat and reduction of carotid intima-media thickness","volume":"126","author":"Burchardt","year":"2016","journal-title":"Pol Arch Med Wewn"},{"key":"10.1016\/j.eprac.2025.06.027_bib85","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5308582","article-title":"DPP-4 inhibitors as treatments for type 1 diabetes mellitus: a systematic review and meta-analysis","volume":"2018","author":"Wang","year":"2018","journal-title":"J Diabetes Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib86","article-title":"Long-term gamma-aminobutyric acid (GABA) treatment fails to regain beta-cell function in longstanding type 1 diabetes in a randomized trial","volume":"15","author":"Hill","year":"2025","journal-title":"Scientific Rep"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib87","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1464-5491.2011.03331.x","article-title":"Effect of sitagliptin on glucose control in adult patients with Type 1 diabetes: a pilot, double-blind, randomized, crossover trial","volume":"28","author":"Ellis","year":"2011","journal-title":"Diabetic Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4158\/EP12100.OR","article-title":"Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial","volume":"19","author":"Garg","year":"2013","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.027_bib89","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1016\/j.diabres.2013.01.020","article-title":"Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study","volume":"100","author":"Hari Kumar","year":"2013","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.027_bib90","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/dom.12453","article-title":"Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study","volume":"17","author":"Schopman","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib91","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/dme.13046","article-title":"Saxagliptin co-therapy in C-peptide negative Type 1 diabetes does not improve counter-regulatory responses to hypoglycaemia","volume":"33","author":"George","year":"2016","journal-title":"Diabet Med"},{"issue":"7","key":"10.1016\/j.eprac.2025.06.027_bib92","first-page":"28","article-title":"Effect of linagliptin on incretin-axis and glycaemic variability in T1DM","volume":"66","author":"Mukherjee","year":"2018","journal-title":"J Assoc Physicians India"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.027_bib93","doi-asserted-by":"crossref","first-page":"e1529","DOI":"10.1210\/clinem\/dgab026","article-title":"Islet function and insulin sensitivity in latent autoimmune diabetes in adults taking sitagliptin: a randomized trial","volume":"106","author":"Yang","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.027_bib94","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s00125-024-06265-7","article-title":"The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial","volume":"67","author":"Elbarbary","year":"2024","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.eprac.2025.06.027_bib95","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1111\/dom.15958","article-title":"The impact of vildagliptin as an add-on therapy on matrix metalloproteinase-14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non-alcoholic steatohepatitis: a randomized controlled trial","volume":"26","author":"ElKabbany","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib96","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/BF00404025","article-title":"Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans","volume":"34","author":"Hartter","year":"1991","journal-title":"Diabetologia"},{"issue":"Suppl 2","key":"10.1016\/j.eprac.2025.06.027_bib97","doi-asserted-by":"crossref","first-page":"78","DOI":"10.2174\/1874104501105010078","article-title":"Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function","volume":"5","author":"Adeghate","year":"2011","journal-title":"Open Med Chem J"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.027_bib98","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.06.027_bib99","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.2337\/dc06-0042","article-title":"A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes","volume":"29","author":"Edelman","year":"2006","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.027_bib100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.2337\/dc06-1026","article-title":"Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes","volume":"30","author":"Marrero","year":"2007","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.eprac.2025.06.027_bib101","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3810\/pgm.2013.05.2635","article-title":"Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy","volume":"125","author":"Herrmann","year":"2013","journal-title":"Postgrad Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.06.027_bib103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CRD.0000000000000513","article-title":"Cagrilintide: a long-acting amylin analog for the treatment of obesity","volume":"32","author":"D'Ascanio","year":"2024","journal-title":"Cardiol Rev"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib104","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/mds.28124","article-title":"Diabetes causes dysfunctional dopamine neurotransmission favoring nigrostriatal degeneration in mice","volume":"35","author":"P\u00e9rez-Taboada","year":"2020","journal-title":"Mov Disord"},{"issue":"4","key":"10.1016\/j.eprac.2025.06.027_bib105","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes","volume":"34","author":"Defronzo","year":"2011","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eprac.2025.06.027_bib106","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1111\/dom.14800","article-title":"Bromocriptine quick-release as adjunct therapy in youth and adults with type 1 diabetes: a randomized, placebo-controlled crossover study","volume":"24","author":"Tell","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib107","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1210\/jc.2016-1451","article-title":"Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes","volume":"101","author":"Kuhadiya","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.eprac.2025.06.027_bib109","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1210\/er.2017-00191","article-title":"Obesity in type 1 diabetes: pathophysiology, clinical impact, and mechanisms","volume":"39","author":"Corbin","year":"2018","journal-title":"Endocr Rev"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2025.06.027_bib110","first-page":"S27","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes\u20142025","volume":"48","year":"2024","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.eprac.2025.06.027_bib111","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/19322968241305647","article-title":"Determinants of liraglutide treatment discontinuation in type 1 diabetes: a post hoc analysis of adjunct one and adjunct two randomized placebo-controlled clinical studies","volume":"19","author":"Shah","year":"2025","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"10.1016\/j.eprac.2025.06.027_bib112","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/dom.12882","article-title":"Dapagliflozin in patients with type 1 diabetes: a post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting \u03b2-hydroxybutyrate levels in a phase IIa pilot study","volume":"19","author":"Henry","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.06.027_bib113","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/dia.2018.0246","article-title":"Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.eprac.2025.06.027_bib114","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.2147\/DMSO.S240903","article-title":"SGLT2 inhibitors in the management of type 1 diabetes (T1D): an update on current evidence and recommendations","volume":"16","author":"Maffei","year":"2023","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"S3","key":"10.1016\/j.eprac.2025.06.027_bib116","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/dia.2023.0442","article-title":"Real-world evidence of automated insulin delivery system use","volume":"26","author":"Considine","year":"2024","journal-title":"Diabetes Technol Ther"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:16:10Z","timestamp":1761930970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25009425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":105,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1530891X25009425"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.06.027","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Noninsulin Therapies in Management of Type 1 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}